GDF-11 vs Teriparatide
A side-by-side research comparison of GDF-11 and Teriparatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | GDF-11 | Teriparatide |
|---|---|---|
| Full name | Growth Differentiation Factor 11 | Teriparatide (PTH 1-34) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved drug (prescription) |
| Mechanism | Signals through activin type II receptors and SMAD2/3 to restore stem cell function, promote neurogenesis, and improve vascular remodeling in the context of aging. | Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength. |
| Molecular weight | 12,500 Da | 4117.8 Da |
| Half-life | 6-8 hours | ~1 hour (subcutaneous) |
| Bioavailability | Moderate (SubQ/IV) | ~95% subcutaneous |
| Typical dose | 0.1-0.5 mg/kg (research) | 20 mcg once daily (medical) |
| Frequency | Daily (animal studies) | Once daily |
| Route | Subcutaneous | Subcutaneous injection |
GDF-11 reported benefits
- Potential tissue rejuvenation
- Neurogenesis stimulation
- Cardiac hypertrophy reversal
- Muscle stem cell activation
- Vascular remodeling
Teriparatide reported benefits
- Actively builds new bone
- Increases bone mineral density
- Reduces fracture risk (medical)
- Supports bone healing
Related comparisons
Research and educational reference only. Not medical advice.